Autres langues Belite Bio, Inc

Actions

BLTE

US07782B1044

Temps réel estimé Cboe BZX Autres places de cotation 17:17:48 07/06/2024			Varia. 5j.	Varia. 1 janv.
48,47 ^USD	-0,47 %		-1,55 %	+5,33 %

14/05	Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
14/05	Belite Bio, Inc déclare ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	14/05
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	14/05
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Belite Bio's Q1 Loss Narrows	14/05
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update	14/05
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results	08/05
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant	06/05
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	06/05
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	06/05
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting	01/05
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	26/04
Belite Bio Announces $25 Million Registered Direct Offering	26/04
Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan	22/04
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom	18/04
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease	25/03
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	22/03
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22/03
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Belite Bio, Inc

Actions

BLTE

US07782B1044

Autres langues

Filtres